open access

Vol 89, No 1 (2021)
Letter to the Editor
Submitted: 2020-07-11
Accepted: 2020-08-03
Published online: 2020-12-17
Get Citation

A review of Ciclesonide in COVID-19. Still a long way to go

Kunal Deokar1, Mehul Agarwal1, Naveen Dutt1, Nishant Chauhan1, Ram Niwas1, Benhur Joel Shadrach1, Gopal Chawla1
DOI: 10.5603/ARM.a2020.0173
·
Pubmed: 33471354
·
Adv Respir Med 2021;89(1):79-81.
Affiliations
  1. Pulmonary, Critical Care & Sleep Medicine, Department of Pulmonary Medicine, All India Institute of Medical Sciences (AIIMS), Jodhpur, India

open access

Vol 89, No 1 (2021)
LETTERS
Submitted: 2020-07-11
Accepted: 2020-08-03
Published online: 2020-12-17

Abstract

As no definitive therapy or vaccine is yet available for COVID-19, in a desperate attempt repurposed drugs are being explored as an option. A drug repurposing study identified Ciclesonide as a potential candidate. We reviewed the available evidence and clinical trials on the use of Ciclesonide in COVID-19. At present the evidence is limited to a report of three cases. However, five clinical trials are underway, and their results will help in elucidating the role of Ciclesonide in COVID-19.

Abstract

As no definitive therapy or vaccine is yet available for COVID-19, in a desperate attempt repurposed drugs are being explored as an option. A drug repurposing study identified Ciclesonide as a potential candidate. We reviewed the available evidence and clinical trials on the use of Ciclesonide in COVID-19. At present the evidence is limited to a report of three cases. However, five clinical trials are underway, and their results will help in elucidating the role of Ciclesonide in COVID-19.

Get Citation

Keywords

COVID 19; ciclesonide; repurposed drug

About this article
Title

A review of Ciclesonide in COVID-19. Still a long way to go

Journal

Advances in Respiratory Medicine

Issue

Vol 89, No 1 (2021)

Article type

Letter to the Editor

Pages

79-81

Published online

2020-12-17

DOI

10.5603/ARM.a2020.0173

Pubmed

33471354

Bibliographic record

Adv Respir Med 2021;89(1):79-81.

Keywords

COVID 19
ciclesonide
repurposed drug

Authors

Kunal Deokar
Mehul Agarwal
Naveen Dutt
Nishant Chauhan
Ram Niwas
Benhur Joel Shadrach
Gopal Chawla

References (9)
  1. Worldometers. Available online: www.worldometers.info/coronavirus/. [Last accessed at: 15.07.2020].
  2. Global Initiative for Asthma. Global strategy for asthma management and prevention. Updated 2020. Available online: https://ginasthma.org/wp-content/uploads/2020/06/GINA-2020-report_20_06_04-1-wms.pdf.[Last accessed at: 13.07.2020].
  3. Jeon S, Ko M, Lee J, et al. Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs. Antimicrob Agents Chemother. 2020; 64(7).
  4. Matsuyama S, Kawase M, Nao N, et al. The inhaled corticosteroid ciclesonide blocks coronavirus RNA replication by targeting viral NSP15. Available online: www.biorxiv.org/content/10.1101/2020.03.11.987016v1.full.pdf. [Last accessed at: 13.07.2020]. .
  5. Van den Broeke C, Radu M, Chernoff J, et al. An emerging role for p21-activated kinases (Paks) in viral infections. Trends Cell Biol. 2010; 20(3): 160–169.
  6. Finnen RL, Roy BB, Zhang H, et al. Analysis of filamentous process induction and nuclear localization properties of the HSV-2 serine/threonine kinase Us3. Virology. 2010; 397(1): 23–33.
  7. Van den Broeke C, Radu M, Deruelle M, et al. Alphaherpesvirus US3-mediated reorganization of the actin cytoskeleton is mediated by group A p21-activated kinases. Proc Natl Acad Sci U S A. 2009; 106(21): 8707–8712.
  8. Maruta H, He H. PAK1-blockers: potential therapeutics against COVID-19. Med Drug Discov. 2020; 6: 100039.
  9. Iwabuchi K, Yoshie K, Kurakami Y, et al. Therapeutic potential of ciclesonide inahalation for COVID-19 pneumonia: Report of three cases. J Infect Chemother. 2020; 26(6): 625–632.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Czasopismo Pneumonologia i Alergologia Polska dostęne jest również w Ikamed - księgarnia medyczna

Wydawcą serwisu jest "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl